Compare Kraft Heinz Co (KHC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kraft Heinz Co vs GeneDx Holdings Corp — how do they compare? Kraft Heinz Co trades at $22.29 (market cap $26.66B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Kraft Heinz Co is far larger — about 13.2× GeneDx Holdings Corp's market cap, and Kraft Heinz Co pays a 7.12% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kraft Heinz Co for 129 Days and GeneDx Holdings Corp for 19 Days on average.
| KHC | WGS | |
|---|---|---|
Market Cap | $26.66B | $2.02B |
Volume | 31,300,109 | 734,640 |
Sector | Consumer Staples | Health |
52-Week High | $27.62 | $167.51 |
52-Week Low | $21.21 | $34.51 |
Typical Hold Time | 129 Days | 19 Days |
Enterprise Value | $42.98B | $2.05B |
Dividend Yield | 7.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $22.08, up 0.45% on the day, with a bearish technical outlook despite recent earnings beats. The stock shows mixed signals with a low P/E of 13.04 and P/B of 0.74, but negative profitability metrics including a net income margin of -13.64% and ROE of -8.78% reflect challenges from a recent $5.85B net loss in 2025. The company maintains strong operating cash flow of $4.46B and a dividend yield near 6.5%, supported by ongoing brand reinvestment efforts.
The investment outlook is cautious; valuation discounts may attract value investors, but persistent volume declines and high debt pose significant risks. Analyst consensus is mixed with a $24.50 price target, yet only 11.43% recommend buying. Key catalysts include successful turnaround execution and new product launches, though competitive pressures and margin recovery remain critical hurdles for sustained shareholder value.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
